January 30, 2015
On January 26, 2015, SNMMI submitted comments to the Drug Enforcement Administration (DEA) regarding a regulation that requires registration to administer the radiotracer drug, DaTscan™. DaTscan™ is the only imaging agent used to differentiate between essential muscle tremors and Parkinsonian syndromes such as Parkinson's disease. As DaTscan is a cocaine derivative, it is classified as a Schedule II drug through the Controlled Substances Act. SNMMI commented that although DaTscan™ is derived from cocaine, there has been no evidence of substance abuse to date. Furthermore, classifying DaTscan™ as a Schedule II substance inadvertently limits patient access to DaTscan™.